Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The U.S. label does not establish renal pharmacokinetics. UCSF and the handbook provide additional recommendations; these cannot be called matching renal-label protocols.
Check source scope before reading a dose
UCSF - atovaquone in dialysis
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
Institutional dialysis regimen; no numeric renal adjustment bands.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: Institutional dialysis regimen; no numeric renal adjustment bands. Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
For adults intolerant of trimethoprim/sulfamethoxazole, Pneumocystis prevention uses 1500 mg orally daily with food. Mild-disease treatment uses 750 mg twice daily with food. The source's dialysis table retains these same regimens.
This is institutional dialysis guidance, not proof that an official label studied renal pharmacokinetics. Use the severity-specific Pneumocystis pathway; do not apply this mild-disease regimen to severe disease.
RDM30-048-atovaquone-1 · Source locator: UCSF - atovaquone in dialysis; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.